Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
7 Tips for efficient study start-up: No.1) Involve Canadian oncologists early on and gather country-specific insight regarding possible enrollment…
In this interview, Susanne Picard, Founder & President of SPharm Inc., answers questions about the Canadian regulatory environment and dispels…
In this interview Janet Manzo, Executive Director of the Ontario Cancer Research Ethics Board, discusses the development of a province-wide…
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
In this interview, Marjorie Morrison, CEO of the Canadian Cancer Action Network, talks about the important role patient advocacy groups…
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…